iRhythm Q2 Revenue Beats, Loss Narrows; $50M Baxter Settlement and $287.5M VitalConnect Acquisition Announced
IRTC sits 25% above its 52-week low of $100.846 on elevated volume (2.1× avg).
Summary
iRhythm Holdings reported Q2 2026 revenue of $224.2M, beating estimates, and a near-breakeven net loss. The company also announced a $50M patent settlement and a $287.5M acquisition of VitalConnect.
Key Events · Earnings and Guidance · IRTC
-
Q2 Revenue Beats Consensus
Revenue of $224.2M grew 20% YoY, exceeding the $219.3M consensus estimate. Net loss narrowed to $0.4M from $14.2M in Q2 2025, and Adjusted EBITDA reached $43.3M.
-
$50M Baxter Patent Settlement
On July 31, 2026, iRhythm paid $50M to settle all outstanding patent litigation with Baxter, Welch Allyn, and BardyDx, securing a worldwide, royalty-free license to the disputed cardiac monitoring patents.
-
$287.5M VitalConnect Acquisition
On August 5, 2026, iRhythm agreed to acquire VitalConnect for $237.5M in cash and $50M in stock, expanding its wearable biosensor and ambulatory cardiac monitoring capabilities. The deal is expected to close by end of 2026.
-
Securities Class Action Settlement
Recorded a $14.0M net litigation settlement expense ($45.0M gross, $40.0M expected insurance recovery) to resolve the putative securities class action.
Analysis · IRTC · Industrial Applications And Services
A strong Q2 saw iRhythm deliver revenue of $224.2M, beating the $219.3M consensus, and swing to an adjusted net income. Subsequent to quarter-end, the company disclosed a $50M patent settlement with Baxter and a $287.5M acquisition of VitalConnect—moves that materially reshape its financial and competitive position.
At the time of this filing, IRTC was trading at $126.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $100.85 to $212.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.